Evolent Health Confirms Q2 and Full-Year Adjusted EBITDA Projections Amidst Strong Business Trends Evolent Health maintains its Adjusted EBITDA expectations for Q2 and the full year, citing positive oncology trends and enhanced revenue forecasts for 2026.

Evolent Health Confirms Q2 and Full-Year Adjusted EBITDA Projections Amidst Strong Business Trends #USA #Washington #Evolent_Health #Adjusted_EBITDA #John_Johnson